Phase 3 Ovarian Cancer Trial, Recruiting NCT03059173 Sponsor: University Hospital, Lille Condition: Ovarian Cancer
Back to Ovarian Cancer

Phase 3 Ovarian Cancer Trial, Recruiting

NCT03059173
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are trying to become pregnant
  • People who have been diagnosed with Polycystic Ovary Syndrome (PCOS) based on specific medical criteria, including having a high number of follicles in the ovaries, irregular menstrual cycles, and/or high levels of male hormones (at least two of these three signs must be present)
  • People who have never been treated with a medication called clomiphene citrate (CC), or whose previous clomiphene citrate treatment ended more than 3 months ago
  • People who have received full information about the trial and have signed a consent form
  • People who are covered by social security

Who may not be able to join:

  • People who have had a bad reaction or intolerance to clomiphene citrate during a previous treatment
  • People with a Body Mass Index (BMI) above 35
  • People whose irregular or absent ovulation is caused by another condition that requires its own specific treatment, such as high prolactin levels or a hormone imbalance related to the brain (confirm with trial site)
  • People who are already pregnant at the time the trial medication would begin
  • People where another medical reason — in either the female or male partner — is contributing to difficulty conceiving
  • People who have previously had a surgical procedure on the ovaries called ovarian drilling
  • People whose blood test shows they are not protected against rubella (German measles)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 19 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Goeffrey Robin, MD, University Hospital, Lille

Phone: 320446252

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Registry
ClinicalTrials.gov
Start date
12 September 2023
Est. completion
12 September 2027

Where this trial is recruiting

🇫🇷 France

Primary endpoints

Total resistance rate under CC for ovulation induction in patients with PCOS.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov